Mushrooms and Neuroinflammation
49 weeks double-blind RCT with MMSE improvement in early Alzheimer's patients using erinacine A-enriched mycelium
Li and colleagues (2020) conducted a 49-week double-blind placebo-controlled trial of erinacine A-enriched Hericium erinaceus mycelium in early Alzheimer's disease patients. Significant improvement in Mini Mental State Examination (MMSE) scores was documented. This is the longest and most clinically rigorous lion's mane neuroinflammation trial, and it sits at the end of a mechanistic chain that begins with microglia data.
Li et al., Frontiers in Aging Neuroscience, 2020
BV2 microglia
Kushairi et al. (2019) showed lion's mane extract reduces nitric oxide production in LPS-activated BV2 microglia (the laboratory model of neuroinflammation), the most direct cell-level evidence for brain inflammation reduction
MPTP + Parkinson's
Lee et al. (2020) showed erinacine A attenuates dopaminergic neuron damage in the MPTP Parkinson's model, extending the neuroinflammation evidence beyond Alzheimer's to a second neurodegenerative disease
Erinacine S + neurosteroids
Lin et al. (2023) showed erinacine S protects oligodendrocytes and promotes neuronal regeneration by inducing neurosteroid accumulation, a novel mechanism not covered in competitor content
Li et al., Frontiers in Aging Neuroscience, 2020
View as image ↗Neuroinflammation is not peripheral inflammation that happens to affect the brain. It is a distinct process mediated by microglia, the brain's resident immune cells, which when chronically activated produce inflammatory mediators (nitric oxide, cytokines, reactive oxygen species) that damage neurons and accelerate neurodegeneration. In Alzheimer's disease, Parkinson's disease, and multiple sclerosis, chronic microglial activation is a disease-perpetuating factor rather than just a symptom.
Lion's mane has the most complete mechanistic evidence chain for anti-neuroinflammatory activity among medicinal mushrooms: direct microglia data, Alzheimer's and Parkinson's animal model confirmation, and a 49-week human RCT with clinical cognitive improvement. No consumer article assembles this chain. For the broader mushroom inflammation overview, see how mushrooms fight inflammation: NF-kB, COX-2, and beyond.
Key Takeaways
- Kushairi and colleagues (2019) showed lion's mane extract suppresses H2O2-induced oxidative damage and LPS-induced neuroinflammation in HT22 hippocampal neurons and BV2 microglia, including direct reduction of nitric oxide production in the primary cell model of brain inflammation
- Tsai-Teng and colleagues (2016) demonstrated erinacine A-enriched mycelium reduces Alzheimer's-related pathologies in APPswe/PS1dE9 transgenic mice, confirming the in vitro anti-neuroinflammatory effects translate to a disease-relevant animal model
- Li and colleagues (2020) conducted a 49-week double-blind placebo-controlled RCT in early Alzheimer's patients using erinacine A-enriched mycelium and found significant improvement in MMSE scores, providing the clinical validation of the mechanistic chain
- Lee and colleagues (2020) showed erinacine A protects dopaminergic neurons against MPTP-induced damage in a Parkinson's disease model, establishing that lion's mane's neuroprotective effects extend beyond Alzheimer's disease
- Lin and colleagues (2023) identified that erinacine S protects oligodendrocytes and promotes neuronal regeneration by inducing neurosteroid accumulation, a completely novel mechanism not covered in any consumer content
- Mori and colleagues (2015) documented general anti-inflammatory effects of H. erinaceus in an adipocyte-macrophage co-culture system, showing cytokine suppression through multiple inflammatory signaling pathways
Microglia: The Brain's Immune Cells and the Direct Evidence
Microglia are the brain's resident immune cells, derived from different precursors than peripheral immune cells and with distinct activation patterns. In healthy brains, microglia survey their environment, removing cellular debris and responding to infections. In chronic neurodegenerative disease, microglia become persistently activated in a pathological state: they produce nitric oxide (NO), pro-inflammatory cytokines, and reactive oxygen species that damage the surrounding neurons rather than protecting them.
This pathological microglial activation is a key driver of neurodegeneration in Alzheimer's disease, Parkinson's disease, and multiple sclerosis. It is also a research target: compounds that suppress pathological microglial activation while preserving their protective functions could reduce the inflammatory component of neurodegeneration.
Kushairi and colleagues (2019) directly tested lion's mane extract against LPS-activated BV2 microglia, the standard laboratory model for studying pathological microglial activation.[1] LPS (lipopolysaccharide) is a bacterial membrane component that triggers strong inflammatory activation in microglia, mimicking what happens during infection or after amyloid exposure.
The results: lion's mane extract suppressed LPS-induced NO production in BV2 microglia. The same study also tested H2O2-induced oxidative damage in HT22 hippocampal neurons and found protective effects. This is the direct cellular evidence that lion's mane compounds reduce the pathological activation of the brain's primary inflammatory cells.
The Mechanism: From Microglia to Signaling Pathways
The broader anti-inflammatory mechanism involves multiple cytokine suppression pathways. Mori and colleagues (2015) investigated H. erinaceus's anti-inflammatory effects in a co-culture system pairing adipocytes (fat cells) and macrophages, a model that mimics inflammatory tissue signaling.[2]
The study documented suppression of pro-inflammatory cytokine production and NF-kB pathway modulation. NF-kB is the master transcription factor that drives expression of inflammatory genes throughout the body, including in brain immune cells. Its modulation by lion's mane compounds connects the microglia data to the broader anti-inflammatory mechanism that operates across peripheral tissues as well.
The specific lion's mane compounds driving neuroinflammation reduction are primarily the erinacines from the mycelium. Their lipophilic structure allows them to cross the blood-brain barrier directly, making them pharmacologically relevant to processes occurring inside the brain rather than only at its periphery.
From Microglia to Alzheimer's: Tsai-Teng 2016
Tsai-Teng and colleagues (2016) translated the cell-level neuroinflammation data into a disease-relevant animal model, testing erinacine A-enriched mycelium in APPswe/PS1dE9 transgenic mice, a standard Alzheimer's disease model.[3]
The APPswe/PS1dE9 mice carry mutations that cause amyloid plaque accumulation and associated neuroinflammation, modeling the Alzheimer's disease pathological cascade. Erinacine A treatment produced multiple effects: reduction of amyloid plaque deposition, decrease in tau hyperphosphorylation (a second AD hallmark), reduction of neuroinflammatory markers, and improvement in behavioral measures associated with the cognitive deficits these mice develop.
The neuroinflammation reduction is specifically relevant: the erinacine A-treated mice showed lower levels of microglial activation markers and pro-inflammatory cytokines in brain tissue compared to untreated transgenic controls. The same compounds that reduce NO in LPS-activated BV2 microglia in the lab reduce pathological microglial activation in the brains of Alzheimer's model mice.
The 49-Week Clinical Trial: Li 2020 in Early Alzheimer's Patients
Li and colleagues (2020) conducted the most clinically significant lion's mane neuroinflammation study: a 49-week double-blind placebo-controlled pilot trial in patients with diagnosed early Alzheimer's disease.[4]
The intervention: erinacine A-enriched Hericium erinaceus mycelia (1.05g per day) versus placebo for 49 weeks. The primary outcome was the Mini Mental State Examination (MMSE), the widely used global cognitive assessment standard in dementia research.
The result: significant improvement in MMSE scores in the erinacine A group compared to placebo. The study also tracked inflammatory biomarkers in blood and cerebrospinal fluid. Treated patients showed changes in inflammatory marker profiles consistent with reduced neuroinflammation.
49 weeks is the longest duration of any lion's mane cognitive trial. The early Alzheimer's population is the most directly disease-relevant of any studied population. The pilot designation (limited sample size) constrains the strength of the conclusion, but the direction and duration of the effect represent the most clinically meaningful data in the lion's mane neuroinflammation research record.
Li et al. (2020) · Frontiers in Aging Neuroscience
- Population
- Patients with mild Alzheimer's disease
- Intervention
- Three H. erinaceus mycelia capsules per day (350 mg each, 5 mg/g erinacine A) — 1.05 g/day
- Comparator
- Identical-appearing placebo capsules
- Finding
- A 49-week double-blind treatment period following a 3-week screening. The erinacine A group showed improvement on cognitive assessment versus placebo, with biomarker and neuroimaging measures also tracked.
preliminary This is the longest and most disease-relevant lion's mane trial to date, but it remains a small pilot RCT — directionally positive and mechanistically consistent, not yet confirmatory. A large multi-center trial has not been done.
Li et al., Frontiers in Aging Neuroscience, 2020
Beyond Alzheimer's: Parkinson's and Dopaminergic Neurons
Lee and colleagues (2020) extended the neuroinflammation evidence to Parkinson's disease, using the MPTP model (which selectively destroys dopaminergic neurons in the substantia nigra, the brain region affected in Parkinson's).[5]
MPTP produces Parkinson's-like dopaminergic neuron loss partly through oxidative stress and microglial activation in the substantia nigra. Post-treatment with erinacine A attenuated MPTP-induced neurotoxicity: treated animals showed reduced dopaminergic neuron loss and reduced neuroinflammatory markers compared to MPTP-exposed controls without treatment.
The Parkinson's data is important for the neuroinflammation story because it establishes that lion's mane's neuroprotective effects are not specific to Alzheimer's pathology. The erinacines protect dopaminergic neurons against inflammatory damage through the same general anti-neuroinflammatory mechanism that protects cholinergic neurons in Alzheimer's models. The mechanism appears broadly neuroprotective rather than specific to a single disease pathway.
Erinacine S: The 2023 Oligodendrocyte and Neurosteroid Discovery
Lin and colleagues (2023) identified a new dimension to lion's mane's neuroprotective mechanism using erinacine S, a compound distinct from erinacine A.[6]
Erinacine S protected oligodendrocytes (the myelin-producing cells of the CNS) and promoted neuronal regeneration through a neurosteroid accumulation mechanism. Neurosteroids are steroids synthesized in the brain that modulate GABA and NMDA receptor activity, influencing neuronal excitability, neuroprotection, and remyelination.
The finding that erinacine S induces neurosteroid accumulation alongside oligodendrocyte protection represents a new pharmacological mechanism for lion's mane that no consumer content covers. Neurosteroids decline in aging and neurodegenerative disease; compounds that restore neurosteroid levels have potential relevance to multiple neurological conditions including MS, depression, and cognitive aging.
The convergence of erinacine S (neurosteroids + oligodendrocyte protection) and erinacine A (microglial suppression + amyloid reduction) within the same mushroom means lion's mane contains a pharmacological toolkit addressing multiple aspects of neuroinflammation and neurodegeneration simultaneously.
Mechanism Map
Two Erinacines, Two Complementary Neuroprotective Axes
Lion's mane mycelium produces both compounds at once, so a single mushroom acts on inflammation, protein pathology, and repair through distinct routes.
Erinacine A
Microglia + amyloid axis
- Suppresses pathological microglial activation and nitric oxide output
- Reduces amyloid plaque and tau hyperphosphorylation in Alzheimer's mice
- Protects dopaminergic neurons in the MPTP Parkinson's model
Kushairi 2019 · Tsai-Teng 2016 · Lee 2020 · Li 2020 (clinical)
Erinacine S
Regeneration + neurosteroid axis
- Protects oligodendrocytes, the myelin-producing cells of the CNS
- Promotes neuronal regeneration and neurite outgrowth
- Induces neurosteroid accumulation that modulates GABA/NMDA signaling
Lin 2023
The two axes converge: erinacine A calms the inflammatory and protein-aggregation side of neurodegeneration while erinacine S supports myelin and regeneration. No single-target drug spans both, which is why the co-occurrence in one organism is the distinctive part of the lion's mane story.
Source: Kushairi et al. (2019); Tsai-Teng et al. (2016); Lee et al. (2020); Li et al. (2020); Lin et al. (2023)
- Cell & Lab Studiescompleted
Direct suppression of LPS-induced nitric oxide in BV2 microglia and protection of HT22 hippocampal neurons (Kushairi 2019); cytokine and NF-kB suppression in an adipocyte-macrophage co-culture (Mori 2015); oligodendrocyte protection and neurosteroid accumulation from erinacine S (Lin 2023)
- Animal Studiescompleted
Erinacine A reduces amyloid, tau, and neuroinflammatory markers in APPswe/PS1dE9 Alzheimer's mice (Tsai-Teng 2016) and protects dopaminergic neurons in the MPTP Parkinson's model (Lee 2020)
- Case Reports & Early Seriesmissing
No dedicated case-series literature specific to neuroinflammation endpoints
- Small Human Trialscurrent
A 49-week double-blind pilot RCT of erinacine A-enriched mycelium in mild Alzheimer's patients with cognitive improvement and inflammatory-marker tracking (Li 2020); the earlier 16-week MCI RCT (Mori 2009) supports the cognitive signal
- Large Randomized Trialsmissing
No large multi-center trial; no trial with a neuroinflammation biomarker as the primary endpoint
- Meta-Analyses & Systematic Reviewsmissing
No human meta-analysis of lion's mane neuroinflammation outcomes
The mechanistic chain is unusually complete for a medicinal mushroom — direct microglial data, two neurodegenerative animal models, and a 49-week human pilot RCT all point the same direction. But the human evidence stops at small pilot trials, so 'reduces neuroinflammation in people' is mechanistically well-supported and clinically suggestive rather than robustly established.
Aggregate of Kushairi 2019, Mori 2015, Tsai-Teng 2016, Lee 2020, Lin 2023, Li 2020, and Mori 2009
Safety — neurodegenerative disease context
ModerateLion's mane is not a treatment for Alzheimer's or Parkinson's disease
Concern
The clinical evidence for neuroinflammation is a single 49-week pilot RCT in mild Alzheimer's disease plus preclinical animal and cell data. This does not establish lion's mane as a treatment, and it should never replace diagnosed care. Anyone with a neurodegenerative diagnosis is typically on prescribed medication, and supplement interactions and disease-specific risks have not been studied.
What the research says
Treat lion's mane as an educational research topic, not a therapy. If you or a family member has Alzheimer's, Parkinson's, MS, or another neurological condition, any supplement decision should be made with the treating neurologist, not in place of prescribed treatment.
Particularly relevant for: People with a diagnosed neurodegenerative disease or on neurological medication
What to do
Consult the treating physician before use. This article is educational and is not medical advice.
Safety framing based on the pilot-stage status of Li 2020 and the preclinical nature of the remaining evidence
The Bottom Line
Lion's mane has the most complete neuroinflammation evidence chain among medicinal mushrooms. Kushairi 2019 established direct microglial NO suppression in LPS-activated BV2 cells. Tsai-Teng 2016 confirmed erinacine A reduces Alzheimer's pathology and neuroinflammation in transgenic mice. Li 2020 provided the 49-week clinical validation with MMSE improvement in early AD patients. Lee 2020 extended the evidence to Parkinson's dopaminergic neuron protection. Lin 2023 added erinacine S's neurosteroid accumulation and oligodendrocyte protection as a distinct novel mechanism.
Frequently Asked Questions
Sources & References
- 1RTHM-01078·Kushairi, Naufal et al. (2019). “Lion's Mane Mushroom, Hericium erinaceus (Bull.: Fr.) Pers. Suppresses H2O2-Induced Oxidative Damage and LPS-Induced Inflammation in HT22 Hippocampal Neurons and BV2 Microglia..” Antioxidants (Basel.Study breakdown →PubMed →↩
- 2RTHM-00726·Mori, Koichiro et al. (2015). “The Anti-Inflammatory Effects of Lion's Mane Culinary-Medicinal Mushroom, Hericium erinaceus (Higher Basidiomycetes) in a Coculture System of 3T3-L1 Adipocytes and RAW264 Macrophages..” International journal of medicinal mushrooms.Study breakdown →PubMed →↩
- 3RTHM-00452·Tsai-Teng, Tzeng et al. (2016). “Erinacine A-enriched Hericium erinaceus mycelium ameliorates Alzheimer's disease-related pathologies in APPswe/PS1dE9 transgenic mice..” Journal of biomedical science.Study breakdown →PubMed →↩
- 4RTHM-00631·Li, I-Chen et al. (2020). “Prevention of Early Alzheimer's Disease by Erinacine A-Enriched Hericium erinaceus Mycelia Pilot Double-Blind Placebo-Controlled Study..” Frontiers in aging neuroscience.Study breakdown →PubMed →↩
- 5RTHM-01229·Lee, Kam-Fai et al. (2020). “Post-Treatment with Erinacine A, a Derived Diterpenoid of H. erinaceus, Attenuates Neurotoxicity in MPTP Model of Parkinson's Disease..” Antioxidants (Basel.Study breakdown →PubMed →↩
- 6RTHM-01734·Lin, Chun-Yu et al. (2023). “Erinacine S from Hericium erinaceus mycelium promotes neuronal regeneration by inducing neurosteroids accumulation..” Journal of food and drug analysis.Study breakdown →PubMed →↩
- 7RTHM-00165·Mori, Koichiro et al. (2009). “Improving effects of the mushroom Yamabushitake (Hericium erinaceus) on mild cognitive impairment: a double-blind placebo-controlled clinical trial..” Phytotherapy research : PTR.Study breakdown →PubMed →↩